← Back to Search

CAR T-cell Therapy

GDX012 Suspension for IV Infusion for Acute Myeloid Leukemia

Phase 1
Waitlist Available
Research Sponsored by GammaDelta Therapeutics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of GDX012 in people with leukemia who have a positive MRD.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Establish the maximum tolerated dose (MTD) of GDX012
Incidence of dose limiting toxicities (DLTs)
Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs)
+1 more
Secondary outcome measures
Evaluate the antileukemic activity of GDX012

Trial Design

1Treatment groups
Experimental Treatment
Group I: GDX012 Suspension for IV InfusionExperimental Treatment1 Intervention
Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells

Find a Location

Who is running the clinical trial?

GammaDelta Therapeutics LimitedLead Sponsor
Michael Koslowski, MDStudy DirectorGammaDelta Therapeutics Limited

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Apr 2025